This November 11, 2008, 3:35 PM EST web-cast [Click that to listen in!] confirms, in part, what "justrpaul" had reported, over at the Yahoo! stock chatboards, below:
. . . .PROVE-3 (the study for which Vertex had offered interim data at AASLD) will be presented -- formally to FDA very early in the first-quarter of 2009 -- with a very wide-open label copy indication. . . .
First Quarter 2009 -- and very wide field of indicated-patient profiles -- Schering is plainly very far behind Vertex, in this horse-race. No doubt. Perhaps more than two years, even.
No comments:
Post a Comment